Find Academic Supervisors

Annette Juul Vangsted serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences. Her clinical specialization is in Internal Medicine with a focus on Hematology, specifically multiple myeloma. Based at Blegdamsvej 9 in Copenhagen, she maintains an active research profile with 67 documented research outputs and extensive collaborations across Nordic countries and internationally. Dr. Vangsted's research primarily centers on multiple myeloma, with particular emphasis on genetic predisposition, treatment outcomes, epidemiological patterns, and bone disease management. Her work bridges clinical practice with genetic research, examining how genetic variants influence disease risk and progression. She investigates geographical variations in myeloma incidence and outcomes, as well as novel treatment approaches for elderly patients and those with specific genetic profiles. Analysis of her recent publications reveals a clear focus on multiple myeloma across several dimensions: genetic susceptibility (including large genome-wide association studies), treatment efficacy (particularly regarding bone disease management), epidemiological patterns across Nordic countries, and specialized care for elderly populations. Her collaborative approach is evident through numerous multi-center studies involving Nordic Myeloma Study Group and international research teams. Dr. Vangsted actively participates in clinical research through the Nordic Myeloma Study Group, contributing to registry studies and clinical trials that inform treatment guidelines for multiple myeloma. Her work has significant implications for understanding disease mechanisms and improving patient outcomes, particularly in the areas of genetic risk assessment and personalized treatment approaches. She maintains strong research collaborations across Denmark, Sweden, and international institutions, with particular focus on hematological malignancies. Her laboratory and clinical research team works within the Department of Clinical Medicine's hematology division, focusing on translational research that directly impacts clinical practice for myeloma patients.

• Hematology
• Multiple Myeloma
• Cancer Genetics
• +4 more

Torben Barington is a Clinical Professor at the Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, and a Consultant at the Department of Clinical Immunology, Odense University Hospital. He has held this position since August 2001 and continues to be actively involved in research, teaching, and clinical leadership. MD, University of Copenhagen, 1987 Doctoral Thesis (dr.med.), University of Copenhagen, 1996 Specialist in Clinical Immunology, 1998 His research focuses on cellular immunotherapy of cancer , particularly using CAR T-cell and CAR NK-cell technologies, primary immunodeficiencies , and the B-lymphocyte repertoire and immunoglobulin genes . His work bridges fundamental immunology with clinical applications in oncology and immunodeficiency disorders. His recent publications (2024–2025) highlight advancements in CAR T/NK-cell characterization, cytotoxicity assays, clinical translation, and tumor microenvironment interactions. These works reflect a strong trend toward translational immunology , with emphasis on personalized cancer therapy , single-cell technologies , and clinical trial development . Scientific Awards: Aage og Edith Dyssegaards Fonds æreslegat (1993) Silver Medal, University of Copenhagen (1981) He has supervised over 30 thesis students and currently mentors several graduate students in CAR-based cancer immunotherapies. He serves as an examiner for PhD defenses at both the University of Southern Denmark and the University of Copenhagen. He is also actively involved in national scientific leadership, including as Chairman of the Scientific Committee of the Danish Blood Donor Organization since 2011 and as a member of the Advisory Board for Clinical Immunology in the Region of Southern Denmark since 2007. His research is conducted in collaboration with multidisciplinary teams focusing on cellular immunotherapy , clinical immunology , and translational hematology , often in partnership with Odense University Hospital and national blood and immunology networks.

• Clinical Immunology
• Cellular Immunotherapy
• CAR T-cell Technology
• +6 more

Heidi Søgaard Christensen is an Assistant Professor at the Department of Clinical Medicine, Faculty of Medicine, Aalborg University (AAU), Denmark. She is also affiliated with the Center for Clinical Data Science, reflecting her dual expertise in clinical research and data analytics. Her work integrates real-world evidence, population-based cohort studies, and advanced statistical methods to improve understanding and outcomes in complex diseases such as inflammatory bowel disease (IBD) and cancer. Her research interests are centered around clinical data science , inflammatory bowel disease , oncology , immunotherapy , pharmacoepidemiology , and biostatistical methodology . She leverages large Danish national registries to conduct high-impact studies on treatment patterns, drug safety, and disease progression. The 15 most recent publications highlight a strong trend toward real-world evidence generation, particularly in IBD and non-small cell lung cancer. Her work spans clinical outcomes, genetic risk prediction, imaging diagnostics, and methodological innovations such as extensions to Bland-Altman plots for multiple observers. These articles reflect interdisciplinary collaboration across gastroenterology, oncology, radiology, and statistics. PhD supervision: 1 student supervised Media coverage: 1 item, including social media mentions on X (formerly Twitter) Datasets contributed: 7, including those related to immune checkpoint inhibitors, abdominal aortic imaging, and statistical methods She has been actively publishing since 2016, with increasing output over time, demonstrating sustained research productivity. While no formal scientific awards are listed, her contributions to open science via figshare datasets and preprints in medRxiv underscore her commitment to transparency and reproducibility.

• Clinical Data Science
• Inflammatory Bowel Disease
• Oncology
• +12 more

Sören Möller is a Professor in the Department of Public Health at the University of Southern Denmark (SDU) , with affiliations to the SDU Climate Cluster and the OPEN research unit at Odense University Hospital. His academic career spans biostatistics, epidemiology, and biodemography, focusing on health data analysis and climate-health intersections. Education: PhD in Mathematics, SDU (2013) MSc in Mathematics, SDU (2011) BSc in Mathematics with Applied Mathematics, SDU (2008) Research interests center on biostatistical modeling , epidemiological cohort studies , patient-reported outcomes , and climate change impacts on public health . Recent work explores bone mineral density trajectories, cardiovascular mortality in occupational groups, and machine learning applications in hematological disorders. Key trends in his 461+ research outputs include: 100% focus on cohort analysis and biostatistics 55% overlap with quality of life and patient-reported outcomes 48% expertise in diabetic retinopathy and cardiovascular disease Scientific Awards: Best Poster, RKKPs Kvalitetskonference (2022) Annual Publication Prize, SDU Clinical Research Department (2021) As a principal supervisor for PhD projects like AVID and contributor to 6+ active initiatives, he bridges mathematical rigor with practical health research. His collaborations span Denmark and Nordic countries, emphasizing extreme weather event analysis and health equity for visually impaired populations.

• Biostatistics
• Epidemiology
• Biodemography
• +5 more

Ivana Novak is a Professor in the Department of Biology at the University of Copenhagen's Faculty of Science, specializing in Cell Biology and Physiology. Her research group operates within the Cell Biology and Physiology section, focusing on epithelial cell mechanisms in disease contexts, particularly pancreatic pathologies. Contact details include email inovak@bio.ku.dk, phone +45 35 33 02 75, and ORCID 0000-0002-8917-8010. Her primary research explores $$\text{ATP}$$-mediated purinergic signaling, P2X7 receptor functions, and ion channel regulation in pancreatic systems. Key interests include pancreatic cancer progression, beta cell metabolism in diabetes, and epithelial secretion mechanisms. She employs advanced imaging to study real-time $$\text{ATP}$$ dynamics and cellular responses, with significant emphasis on how metabolic alterations drive disease pathways in pancreatic duct and beta cells. Analysis of her 143 research outputs reveals a concentrated focus on pancreatic disorders since 2022, with 8 recent publications demonstrating expertise in $$\text{ATP}$$ signaling networks and ion channel modulation. Her work bridges molecular mechanisms (e.g., $$\text{K}^+$$ channels, $$\text{H}^+$$-$$\text{K}^+$$-$$\text{ATP}$$ase) with clinical implications for cancer and diabetes, showing consistent innovation in targeting purinergic pathways for therapeutic development. Dr. Novak leads an active laboratory dedicated to epithelial biology, as evidenced by her research group's homepage focusing on epithelia. Her collaborative network spans multiple countries, with recent work featured in high-impact journals including Pain , Cell Stem Cell , and International Journal of Cancer . The laboratory maintains strong translational research trajectories investigating pancreatic cancer microenvironments and metabolic disease mechanisms.

• Cell Biology
• Physiology
• Cancer Research
• +5 more

Rikke Faebo Larsen is a researcher at the Department of Clinical Research, University of Southern Denmark, affiliated with the Research unit of Haematology at Odense University Hospital. Her work focuses on improving outcomes for patients with hematological malignancies, particularly multiple myeloma. Dr. Larsen's research interests include: Multiple Myeloma treatment and management Exercise interventions for cancer patients Quality of life assessment in hematological malignancies Bone disease management in myeloma patients Rehabilitation engineering approaches for cancer survivors Pain management strategies for multiple myeloma patients Her recent publications demonstrate a strong focus on exercise interventions for multiple myeloma patients, with several randomized controlled trials and systematic reviews examining how physical activity impacts physical function, bone health, and quality of life. She has also contributed to research on intensive care platforms and patient experiences with pain management. Dr. Larsen serves on the Danish Health Authority working group for revision of care pathways for myeloma (Sundhedsstyrelsen arbejdsgruppe for revision af pakkeforløb for myelomatose) since 2020 and has presented her work at numerous conferences including the EMMY-study on exercise in multiple myeloma. Her research has received media attention in Denmark, with coverage discussing how newly diagnosed myeloma patients can benefit from exercise, and her publications have been widely shared on academic platforms and social media.

• Multiple Myeloma
• Quality of Life
• Bone Disease
• +5 more

Karen Dybkær is a Professor and Senior Researcher at Aalborg University Hospital's Clinical Institute within the Faculty of Health Sciences at Aalborg University, specializing in the Department of Blood Diseases. Her research focuses on hematological malignancies with particular emphasis on blood cancers and biomarker discovery. Her primary research interests include Diffuse Large B-Cell Lymphoma, B Cell Immunology, Multiple Myeloma, and gene expression profiling as evidenced by her extensive publication record. The fingerprint analysis of her work shows strong focus areas in Diffuse Large B-Cell Lymphoma (100%), B Cell Immunology (88%), and Multiple Myeloma (16%). Dr. Dybkær's recent publication trends (2021-2025) show continued productivity with significant contributions to understanding cancer biomarkers, treatment response mechanisms, and molecular profiling in hematological malignancies. Her work spans both basic science and clinical applications, with publications appearing in high-impact journals across hematology and oncology. She has been actively involved in PhD supervision, having mentored 6 doctoral students according to institutional records. Her collaborative research extends across Nordic countries with significant involvement in the Nordic Myeloma Study Group and other international hematology research networks. Dr. Dybkær maintains active engagement with patient communities, as evidenced by her participation in events like the Lyle patient association for lymphoma and leukemia. Her research has received media attention in Denmark, particularly regarding new initiatives in cancer research and her appointment as professor in hematology in 2021.

• Hematology
• Blood Cancers
• B Cell Immunology
• +5 more

Tarec Christoffer El-Galaly is a Clinical Professor and Adjunct Professor at the Department of Clinical Medicine, Aalborg University, with a secondary appointment at Aarhus University starting September 2024. He specializes in hematology and oncology, focusing on clinical management of hematological malignancies, particularly diffuse large B-cell lymphoma (DLBCL). His research integrates clinical trials, prognostic modeling, and advanced imaging techniques. Research interests include: Prognostic indices and risk stratification in lymphoma Machine learning applications in diagnostic algorithms Clinical trial accessibility and healthcare equity Survival analysis and treatment outcomes Recent articles highlight trends in automated imaging analysis (e.g., PET/CT for DLBCL), cost-effectiveness of treatments, and patient-reported outcomes. His work bridges translational research and clinical practice. Awards : Svend Andersen Talent Prize (2019), Kræftens Bekæmpelse Junior Research Prize (2017), Tove Nilsson Research Prize (2017) Supervision includes 8 PhD students, with a focus on lymphoma biology and clinical trial design. He collaborates on datasets like automated PET/CT analysis and cost analyses of myeloma treatments. Active in conferences (e.g., International Molecular Med Tri-Con) and peer review. Labs/teams: Core involvement in hematology research groups at Aalborg University Hospital and Danish-Swedish collaborative networks.

• Hematology
• Lymphoma
• Oncology
• +6 more

Henrik Gregersen is a Clinical Professor at Aalborg University Hospital’s Department of Haematology within the Faculty of Medicine at Aalborg University. His research focuses on hematology, particularly multiple myeloma, monoclonal gammopathy, and the impact of socioeconomic factors on patient outcomes. He is actively involved in clinical trials, such as those evaluating carfilzomib and stem-cell transplantation efficacy, and has contributed to over 86 publications since 1998. Dr. Gregersen’s work spans clinical pharmacology and oncology, with recent studies analyzing chemotherapy-induced neuropathy and immunoglobulin measurement accuracy. He serves on the board of the Danish Hematological Society and has presented at international conferences like the American Society of Hematology Annual Meeting. His research has garnered media attention, including coverage on carfilzomib’s role in extending survival for multiple myeloma patients. Collaboration highlights include the Nordic Myeloma Study Group, emphasizing his role in advancing hematological research and patient care. While no explicit awards are listed, his extensive publication record and leadership roles underscore his contributions to the field.

• Hematology
• Multiple Myeloma Research
• Oncology
• +3 more

Clinical Associate Professor Hanne E. H. Møller is affiliated with the University of Southern Denmark at the Clinical Institute 's Research Unit for Pathology in Odense. Her work focuses on amyloidosis, multiple myeloma, and bone biology. Key Research Areas: Amyloidosis diagnostics, proteasome inhibition in myeloma, mass spectrometry techniques, and bone remodeling. Collaborations: Active in multidisciplinary research networks, particularly in amyloid protein subtyping. Teaching: Involved in medical education (Bachelor of Medicine B12 course). Recent publications highlight advancements in amyloidosis identification and bone anabolic effects of ixazomib in myeloma patients.

• Pathology
• Amyloidosis
• Multiple Myeloma
• +5 more

Morten Rytter Tulstrup serves as a Lecturer in the Department of Public Health within the Faculty of Health and Medical Sciences at the University of Copenhagen. His academic affiliation centers on the Section of Biostatistics, where he conducts research at the intersection of hematology, epidemiology, and pharmacovigilance. His institutional address is Øster Farimagsgade 5 opg. B, 1353 København K. His research spans hematological malignancies, clonal hematopoiesis, and drug safety assessment. Key focus areas include: Mendelian randomization studies for causal inference in testosterone therapy DNA methylation alterations in myelodysplastic syndromes Epidemiological patterns of anabolic steroid complications Clonal evolution in multiple myeloma and acute leukemias Pharmacovigilance methodologies for adverse drug reactions His work integrates genomic, epigenetic, and population-level data to address clinical questions in hemato-oncology. Analysis of his 16 recent publications (2023-2025) reveals consistent focus on hematological disorders with emerging emphasis on Mendelian randomization techniques. His collaborative network spans Danish hospitals and international consortia, particularly in studies involving large population cohorts and genomic databases. Key publication venues include Leukemia , Haematologica , and specialized pharmacology journals. No scientific awards are currently documented in available sources. His research impact is evidenced by social media dissemination across X (formerly Twitter), Bluesky, and Mendeley readership, with several studies picked up by news outlets. Tulstrup participates in multi-institutional collaborations, notably with Rigshospitalet and Copenhagen University Hospital departments. His current work involves Danish population-based studies on clonal hematopoiesis (e.g., COVID-19 hospitalization research) and testosterone-related adverse events. He appears integrated within the university's hematology research ecosystem but no dedicated lab leadership is indicated.

• Hematology
• Oncology
• Epidemiology
• +5 more

Karin Brochstedt Dieperink is a Professor at the Department of Clinical Research, University of Southern Denmark, with key affiliations at Odense University Hospital (OUH) and the KI research environment. She is a leading figure in cancer nursing and family-focused healthcare research, active in the Research Unit of Oncology (Odense), AgeCare – Academy of Geriatric Cancer Research, and FaCe – Family focused healthcare research Center. Her work bridges clinical practice and academic research in oncology, palliative care, and supportive services. Her research interests center on cancer nursing , family-centered care , palliative and end-of-life support , patient-reported outcomes , and health communication . She employs qualitative and integrative methodologies to explore family dynamics, anticipatory grief, and communication challenges in oncology settings. Her recent publications highlight a strong focus on improving patient and family understanding, reducing avoidable hospitalizations, and enhancing home-based cancer treatments. The trends in her recent articles (2016–2025) reflect a consistent commitment to patient and family experiences in cancer care, with emphasis on communication, emotional support, and innovative delivery models like video consultations and home-based therapies. Her work spans disciplines including nursing, oncology, psychology, and healthcare systems, with a strong international collaborative footprint. Scientific Awards: The innovative RAP prize (2019) OUHs Udviklingspris 2018 (2018) Second best poster prize (2016) Best poster prize (2016) She actively supervises PhD students, including M. L. Kidholm, and contributes to academic mentoring through external supervision and guest lectures. Her projects, such as 'Families in the Face of Serious Illness,' reflect her dedication to understanding family health and values in parental cancer. She has been involved in grant-funded research and clinical development initiatives, demonstrating leadership in both research and practice innovation. Karin Brochstedt Dieperink leads and contributes to multiple research centers, including FaCe, AgeCare, and the Research Unit of Oncology, which focus on family-centered and geriatric cancer care. These teams emphasize interdisciplinary collaboration, patient engagement, and translational research to improve outcomes for patients and their families.

• Cancer Nursing
• Palliative Care
• Family-Centered Care
• +9 more

Charlotte Toftmann Hansen is a Clinical Lecturer at the Department of Clinical Research, University of Southern Denmark, with affiliations to Karolinska Institute (KI) and Odense University Hospital (OUH). She specializes in hematology and oncology, particularly focusing on amyloidosis, multiple myeloma, and light chain deposition disease. Primary Affiliation: University of Southern Denmark Collaborations: Karolinska Institute, Odense University Hospital, European Society for Blood and Marrow Transplantation Research Trends: Recent work emphasizes real-world treatment outcomes in multiple myeloma (e.g., teclistamab, belantamab mafodotin), renal responses in light chain deposition disease, and serum free light chains as diagnostic biomarkers. Her studies bridge clinical practice with translational medicine. Scientific Activities: She actively contributes to conferences (e.g., EHA 2025), serves on expert groups (Danish Myeloma Study Group), and participates in editorial work. Collaborations span multi-center observational studies like REALiTEC and Danish ABCD-study.

• Hematology
• Oncology
• Amyloidosis
• +5 more

Jacob Haaber Christensen is a Physician Scientist at the University of Southern Denmark's Faculty of Health Sciences, Department of Clinical Research, and works at Odense University Hospital in the Research unit of Haematology. His research focuses on hematological malignancies, particularly lymphoma treatments and clinical trials. Dr. Christensen's primary research interests include Mantle Cell Lymphoma B-Cell and T-Cell Immunology Novel Therapies including Brentuximab Vedotin and Bispecific Antibodies Progression and Overall Survival metrics Cardiovascular risks in lymphoma patients His recent publications demonstrate expertise in clinical trial analysis, particularly the ECHELON-2 study and Nordic Lymphoma Group trials. His work spans both experimental therapeutics and real-world population-based studies in Denmark. Dr. Christensen has been active in establishing a Phase I unit in Odense, as reported in Danish media in mid-2024. His research output includes 135 publications with significant focus on lymphoma treatment outcomes.

• Hematology
• Oncology
• Lymphoma
• +7 more

Tine Rosenberg is a researcher at the Department of Clinical Research, University of Southern Denmark, affiliated with the Research Unit of Haematology (Odense) and Karolinska Institute (KI). Her work focuses on multiple myeloma, patient-reported outcomes, and treatment-related side effects. Major Collaborations: Nordic Myeloma Study Group (NMSG), Cross-disciplinary Haematological Research Network in Denmark Research Themes: Quality of life assessment, clinical trial analysis, home-based treatment optimization Recent publications examine carfilzomib-lenalidomide-dexamethasone consolidation therapy outcomes and home administration of daratumumab. She actively participates in conference presentations and clinical research networks.

• Hematology
• Medical Research
• Cancer Treatment
• +3 more